- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06581146
En studie for å sjekke leverhelsen hos gutter med XLMTM, en alvorlig genetisk muskeltilstand (EXCEL)
En ikke-intervensjonell, epidemiologisk studie av XLMTM og klinisk uttrykk i leveren
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.
Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.
There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).
In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.
This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Astellas Gene Therapies
- Telefonnummer: 800-888-7704
- E-post: Astellas.registration@astellas.com
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada
- Rekruttering
- Site CA15001
-
-
-
-
California
-
Santa Monica, California, Forente stater, 90401-2072
- Rekruttering
- UCLA Neurological Services
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Boston Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- UPMC Children's Hospital of Pittsburgh
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Rekruttering
- University of Utah
-
-
-
-
-
Leeds, Storbritannia
- Rekruttering
- Site GB44006
-
London, Storbritannia
- Rekruttering
- Site GB44003
-
Oxford, Storbritannia
- Rekruttering
- Site GB44005
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Approximately 50 male participants < 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.
Beskrivelse
Inclusion Criteria:
- Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
- Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
- Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.
Exclusion Criteria:
- Participant is currently enrolled in an interventional study designed to treat XLMTM.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Participants with XLMTM
Pediatric and adolescent participants with XLMTM. |
No investigational drug will be administered to participants in this study. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence rate of cholestasis
Tidsramme: Up to Week 48
|
Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants. |
Up to Week 48
|
|
Point prevalence of cholestasis
Tidsramme: Day 1
|
Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline). |
Day 1
|
|
Prevalence of cholestasis
Tidsramme: Up to 1 year
|
Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline). |
Up to 1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Genetic variants of MTM1
Tidsramme: Up to Week 48
|
The association between genetic variants of MTM1 and cholestasis will be evaluated. |
Up to Week 48
|
|
Risk of cholestasis temporarily associated with environmental modifiers
Tidsramme: Up to Week 48
|
Medication use, immunization history, infectious disease history and dietary habits will be collected. |
Up to Week 48
|
|
Hospitalizations
Tidsramme: Up to Week 48
|
Frequency and reason for hospitalizations will be collected. |
Up to Week 48
|
|
Duration of Hospitalizations
Tidsramme: Up to Week 48
|
Duration of hospitalization visits will be collected. |
Up to Week 48
|
|
Emergency room visits
Tidsramme: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Hepatology specialist visits
Tidsramme: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Scheduled/unscheduled office visits
Tidsramme: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Non-study-specified home healthcare visits
Tidsramme: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Surgeries/procedures
Tidsramme: Up to Week 48
|
Frequency and type will be collected. |
Up to Week 48
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Medical Director, Astellas Gene Therapies
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1600-MA-3536
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .